Member Info for PM2022

Scancell is doing what has done . Don't be surprised when that tanks to below 1p.

Now that the CEO is heavily invested and all is settled I don't see another 50% discount at this market cap. Worst case imo if Val was say 0.90 they could place at 0.75 if they can demonstrate decent progress with CLX. Best case could be 201 deal, 401 deal, significant progress with SPV. Imperial could like CLX if it gets through and at a fairly late stage as well. A decent set of finances for the first time ever with decent revenue generated will attract investment given all the projects in play. Val would still get to 1.50 even in the worst case imo but more likely we will get to 3p plus in the coming months.

Either way not many sellers here so expecting a decent rise as news comes through. We might get some tasters regarding 201 soon that will start moving the SP.

Or more likely you just want him to sell so that your client can buy in on the drop.

I guess Mark buying in so much does not mean 201 will get done but should show something valuable is in the pipeline. Could be 201,401 or even CLX.

News of merger to come

CLX news we are due one

401 deal

signed 201 deal

likely SPV- If imperial then it could be very significant given rep of uni and advanced stage compound compared to other similar ones.

Strong financials if the lab breaks even as anticipated

I would not worry about the slightly quiet period but I always thought based on the deadlines that this stock will get busy in March/April or maybe from next week.

In order to generate interest they need more than one decent piece of news and to take this above warrant price otherwise it will just go up and down. Therefore expecting merger news, 401, presentations, SPV and other news in a short space of time and I think that would be over March/April. Any slight dip above warrant price would allow the share price to go back up once the company gets cash from the warrants likely above about 1.6/1.7p but a deal conclusion should achieve that anyway.

I think a good buy at these prices before the busy period starts because surely at least some news will be positive.

That is AIM. This is not the FTSE.

Must be a boring retirement posting on a stock you are not invested in. Try find excitement elsewhere.

They never had enough time. The CEO just joined at that point so in fact did well to get it over the line although generous.

CLX will progress close to the deal stage hopefully in the coming months. I expect the lab to generate good revenue, if 401 or 201 is done hopefully one is not needed but if it is then they should target no more than 10% late this year or next year.

Point is that I expect the current SP to be bottom and for this to move up from here. Hopefully by then we will be 2p plus but if that is the case the warrant money will mean one is not needed.

It shows it can be done in this market if you can demonstrate good plans.

Expecting decent news flow in the next 2 months here.

Possible SPV. I think Imperial will be huge and attract investment if it successfully moves to SPV. Apparently it is at a later stage compared to other compounds.

Expecting an update on the merger in the coming weeks. Deadline for May is a long stop imo, i'm sure to avoid constantly extending the deadline they have given the maximum date for this to conclude but I think the reality is 201 could be signed by March/April.

Val401 deadline is April but can conclude at any time.

We are due CLX news at some point that could lift us a fair amount.

At this price and market cap it seems like a good hold and add over the next few months. Moving forwards if they can progress with CLX and get a deal done for 201/401 then they can get some warrant money if not then at the end of the year if they show the value for CLX and how close it is to deal stage then they should also target a 5% discount for a change. Potential 35 million for preclinical deal plus huge milestones.

Seems fairly secure at these prices for a good rise imo. Cash until at the end of the year but also they are generating revenue with more contracts to come which can extend this to 2026.

With the CEO heavily invested and so much news due at such a low price I still think we will get to 2p and above in the next 2/3 months.

The main news is CLX, 401 and 201 which are all to come shortly. Big drug development news is what will move this fast.

Revenue helps longer term to attract investment. Still they are getting a collection of contracts and it will all add up and improve the cash runway hopefully into 2026 even without deals or warrants.

This is why this will likely successfully be completed. Work it out yourself and look up the figures yourself:

https://www.jpmorgan.com/content/dam/jpm/commercial-banking/insights/life-sciences/jpmorgan-q2-2023-biopharma-licensing-and-venture-report.pdf

Median upfront payment for oncology for a phase 2 drug: about $100 million

Chances of compound success in phase 2: 30-50%

Cost of trials for phase 2b about = $8.6million

But with Val201 we know the previous trial showed excellent potential but the issue was how the trial was conducted. We know the peptide is safe, reducing the risk of trial failure and showing good efficiency. Also the compound was tested at lower dosage so efficiency could well be much higher than the approx 50% results of the previous trial.

Therefore In view of this investors would be getting potential 15/20 times return possibly much more if they sell it on after phase 2 which I understand was the plan. 15/20 times return for less than 50% risk but I would assume that would be without considering potential royalty payments so considerably higher than 15/20 times return.

It goes back to the point I made a few times before. It costs a company 10s million to get to this stage. They get all this for next to nothing. Therefore provided the IP is sorted which I think has been, I cannot see how 201 will not get signed just my view, logically. Maybe a merger is needed for an exit strategy but it surely is a great investment with big returns for any potential merger company.

You do realise all the foundations were built by the old board. Not saying some things could have been better at the same time my views came from what would happen to the SP due to instability and time lost.

I think if it was better managed the SP would have been higher. Changing all members would lead to SP destruction as it has proven. Placing was done at the second and so predictable.

We move on and as it stands things are good.

Board changes at 6p is what led to the destruction of the share price as time was lost and Mark barely had any time for the placing and resulted in a delayed placing. Those promising to invest are still at it. We had a 60% discount and also free warrants and 60% from a valuation which was already absolutely destroyed. I was the only one here that understood the impact of those changes and was against it.

What that has done is that it has provided an opportunity in my opinion. We have a decent runway of cash and lots of news and significant outcomes due.

One decent outcome we should get a bit more cash from warrants and hopefully no more placing before CLX deal which with an upfront payment if it comes in at 20,30,40 million plus milestones 100 million plus should see us at 15p plus especially if 201 or 401 conclude shortly.

Why did you buy big into the 10p placing then?

No, you sold because you made a profit from the 10p placing. Not much had changed from the rise from 10p to 20p in regards to 201 after the placing other than the announcement of CLX etc.

I accept I was positive but I stick to my views. I believe we are worth multiples of where we are. The current SP is not a fair reflection. At least I am consistent. We can all see the agenda at play.

I wonder where those sells came from. Funny some people just pop up when the agenda suits them.

Nick can I remind you that you purchased what 5-6% of the company and you were ramping away on Telegram whilst selling at the same time. Who can forget the famous presentation that Adam did only to find out you had sold later. I think people follow you not me.

Also to note again you are contradicting your views. Back then the market cap was about 10 million at 10p when you purchased big but at that point you were 100% 201 was not getting done but CLX has progressed since. Now 201 and 401 which was not in the picture before has a better chance even if it has taken a while. The lab has also progressed so either you were wrong or the company is massively undervalued and you know that.

As I said I made the decision to reinvest. Even getting to 2p would be a win but I am confident we can get far higher. People can decide for themselves how to invest.

Getting to 1.60p should double your money. I think with potential 201, 401, SPV and CLX news I am confident but obviously it is speculative.

Depending much on the novelty of the project which CLX ticks massively therefore the upper range. Current valuation undervalues the company significantly. Also without 401 and 201 deals. Aim is to get to IND stage for CLX.

Smartcelle can potentially increase biodiversity therefore the chances of clinical success which in turn should increase the valuation of CLX.

Stage Typical Valuation Range

Lead Formulation (Current) $2M – $20M

IND-Enabling Stage $10M – $50M

Phase 1 Clinical Trial $30M – $100M

Phase 2 (Indication-Specific) $100M – $300M+

Not expecting another placing so hopefully a significant rise in the coming months.

Just the start. Good to have buying and selling going on before the next leg up.

Stronger news expected to come soon.

This platform can massively increase the value of CLX and any potential deal:

1) The smartcell can enhance the solubility and stability of CLX001. It could increase the bioavailability, increasing its therapeutic effectiveness.

2) Better Targeting: The platform may allow for more precise delivery to cancer cells, reducing off-target effects and enhancing safety.

They are building up to one big fat payment for CLX001.

No costs for this project other than to progress within Valirx's lab.

Expecting several different news to come so a good start. Top it up with 201 merger news or CLX update and this will move big.

I was doing research on CLX last night. Indication value for the current stage is 2-20 million but obviously once safety tests are done over the next few months then it will increase by multiples if all goes well. 20 million for more novel compounds which CLX is.

Estimated time 6-18 months for CLX. Then the deal time where average upfront payment is 35 million plus 800 million milestones.

News due on Dundee and Imperial soon. That should move the share price up a fair amount as it will be like another CLX.

https://www.heraldscotland.com/news/24147479.dundee-scientists-discover-method-eliminate-cancer-cells/

Imperial is at a fairly advanced stage. See entire video.

https://www.brrmedia.co.uk/broadcasts/65fb136df4529adbe93ea0d5/valirx-plc-signed-evaluation-agreement-with-imperial-college-london/

Hopefully an update on 201 merger soon as well. 401 deal can land at anytime in the coming weeks/months.

I enjoyed listening to the spotify podcast and they are big on women's health and in my view they sell it well.

TBC Capitals also have strong views on AI as demonstrated on the podcast so I think that could drive investment into Val201 if they are following through with this to TRX but I would think by now hopefully the funding has been achieved. Don't forget Ken works for both. It could be a great selling point for the merger to complete whatever they have if it relates to AI tools and how it helps save time and supercharge revenue growth.

News due from so many different areas so hopefully an interesting few weeks ahead.